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A B S T R A C T
Background
Some groups of people have a greater risk of developing common non-melanoma skin cancers (NMSC).
Objectives
To evaluate interventions for preventing NMSC in people at high risk of developing NMSC.
Search methods
We searched the Cochrane Skin Group Specialised Register (March 2007), the Cochrane Central Register of Controlled Trials (The Cochrane
Library Issue 1, 2007, MEDLINE (from 2003 to March 2007), EMBASE (from 2005 to March 2007), the metaRegister of Controlled Trials
(February 2007). References from trials and reviews were also searched. Pharmaceutical companies were contacted for unpublished trials.
Selection criteria
Randomised controlled trials of adults and children at high risk of developing NMSC.
Data collection and analysis
Two review authors independently selected studies and assessed their methodological quality.
Main results
We identified 10 trials (7,229 participants) that assessed a variety of interventions.
One trial found T4N5 liposome lotion significantly reduced the rate of appearance of new BCCs in people with xeroderma pigmentosum.
One of three trials of renal transplant recipients showed a significantly reduced risk of new NMSCs when acitretin was compared to placebo
(relative risk (RR) 0.22 95% confidence interval (CI) 0.06 to 0.90) and no significant diCerence in risk of adverse events in two trials (RR 1.80,
95% CI 0.70 to 4.61).
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In three trials conducted in people with a history of NMSC, the evidence was inconclusive for the development of BCCs for retinol or
isoretinoin. However the risk of a new SCC in one trial (HR 1.79, 95% CI 1.16 to 2.76) and adverse events in another trial (RR 1.76, 95% CI
1.57 to 1.97) were significantly increased in the isotretinoin group compared with placebo.
In one trial selenium showed a reduced risk of other types of cancer compared with placebo (RR 0.65, 95% CI 0.50 to 0.85) but also a
significantly elevated risk of a new NMSC (HR 1.17, 95% CI 1.02 to 1.34). The evidence for one trial of beta-carotene was inconclusive; and
there was a trend towards fewer new NMSC in a trial of a reduced fat diet (RR 0.16, 95% CI 0.02 to 1.31), p = 0.09.
Authors' conclusions
Some preventative treatments may benefit people at high risk of developing NMSC, but the ability to draw firm conclusions is limited by
small numbers of trials, oMen with one trial per intervention or with inconsistent results between studies.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions for preventing of non-melanoma skin cancers in high-risk groups
Non-melanoma skin cancer is still the most common cancer in the UK, the United States and Australia. People at increased risk of getting
non-melanoma skin cancer include those with lowered immunity, a history of non-melanoma skin cancer, rare inherited genetic skin
disorders, trauma to the skin, exposure to arsenic, albinism or having had psoralen and ultraviolet A treatment. Very few studies have been
conducted in people at increased risk of NMSC.
For people with Xeroderma pigmentosum (a rare inherited genetic skin disorder) topical application of T4N5 liposome lotion is beneficial in
reducing the rate of appearance of new basal cell carcinomas, however it may increase the risk of a new squamous cell carcinoma. Acitretin
in renal transplant recipients may be of some benefit, however, high doses of acitretin are associated with an increased number of adverse
events. Retinol or a reduced fat diet may be worth trying for people with a history of non-melanoma skin cancer. Further prevention studies
for people at increased risk of non-melanoma skin cancer are needed.
Interventions for preventing non-melanoma skin cancers in high-risk groups (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Skin cancer is the most common type of cancer in humans (Martinez
2001). Around 97% of skin cancers are epithelial in origin and are
either basal cell carcinomas (BCCs) or squamous cell carcinomas
(SCCs), collectively known as non-melanoma skin cancer (NMSC).
In this review we shall not address precursor lesions for NMSC, i.e.
solar keratoses and Bowen's disease.
BCC is defined as a slow-growing, locally invasive, malignant,
epidermal skin tumour that mainly aCects people with light
coloured skins (Telfer 1999). BCCs are the most common malignant
growth found in humans and originate from basal cells of the
epidermis (Lang 1991; Telfer 1999). SCCs are generally more
aggressive than BCCs and originate in skin cells that produce
keratin. Unlike BCC, which has no reported precursor lesions, there
are two principal precursors of SCC: actinic (solar) keratoses (AKs)
and Bowen's disease (intra-epidermal carcinoma; IEC), both of
which are described as carcinoma-in-situ. SCC is distinguished from
carcinoma-in-situ by having an invasive component (i.e. involving
connective tissue and blood vessels in the dermis), which can be
determined histologically (Goldman 1998).
Epidemiology
The incidence of NMSC is unclear but is known to increase the
closer a person lives to the equator. Using data from 1947 to 1948,
from 10 US cities, age-adjusted rates of skin cancer were found
to double for each 3°48' of latitude toward the equator (Auerbach
1961). In the year 2000 62,200 cases of NMSC were diagnosed in the
UK (CRUK 2004). This is, however, likely to be an under-estimate
due to the incomplete registrations of these tumours and the fact
that they very rarely lead to death. Increasing numbers of NMSCs
are diagnosed and treated within family practice surgeries using
destructive techniques such as cryotherapy (tissue destruction by
freezing), which preclude histological confirmation of the lesion.
Despite this conservative estimate, NMSC is still the most common
cancer in the UK, United States and Australia (Alam 2001; Eedy 2000;
Staples 1998; Stern 1999). NMSC accounts for 75% of all cancers in
Australia and is approximately 30 times more prevalent than lung
cancer among men, and 10 times more common than breast cancer
in women (AIHW 2003). In the USA the incidence is estimated at over
one million people per year, which means it is roughly five times
more common than prostate and breast cancer (ACS 2003). In South
Wales (United Kingdom) the incidence rate of NMSC between 1988
and 1998 rose from 173.5 to 265.4 per 100,000 per year, an overall
increase of 16% for SCC and 66% for BCC (Holme 2000). In Australia,
data from a population based study conducted between 1985 and
1995 showed that incidence rates for BCC increased by 19% to 788
per 100,000, and for SCC there was a 93% rise from 166 to 321 per
100,000 (Staples 1998).
Worldwide, the incidence of BCC shows a continued rise but for
SCC there is a varied picture with increasing incidence in some
countries and rates reaching a plateau in others (Harris 2001). This
increase in incidence may be due to increased histopathological
examination of suspicious lesions, an increased awareness of,
and concern about these tumours and an increased number of
dermatologists. SCC incidence rates may be levelling oC in some
countries because a larger number of precursor lesions are being
removed by physicians before they can develop into SCCs (Harris
2001) and through the use of sunscreens, which are thought to be
more protective for SCCs than BCCs (Green 1999).
Causes and risk factors
The five year recurrence rate of SCCs is influenced by the anatomical
site, degree of diCerentiation and depth of tumour (Rowe 1992).
SCCs greater than 2 cm in diameter have a 5 year recurrence rate
which is double that of an SCC less than 2 cm (Rowe 1992). If depth
of the lesion is greater than 4 mm, the 5 year recurrence rate is 17%
(Rowe 1992), while lesions on the ears or lips (which are generally
aggressive) have 2 to 3 times the 5 year recurrence rate of SCC of the
same depth in other anatomical regions (Alam 2001).
The most important risk factors for NMSC are thought to be
people's age, skin type and exposure to sunlight (ultraviolet (UV)
radiation). UV radiation is subdivided, based on wavelength, into
UVA (long wave), UVB (burning rays), and UVC (germicidal rays) and
it plays a role in NMSC development through several mechanisms.
People are not exposed to UVC since the ozone layer filters it out,
preventing it from reaching the earth's surface. UVB is responsible
for most skin burning aMer sun exposure. UVA has a longer
wavelength and can therefore penetrate the skin more deeply. In
addition to causing mutations in DNA, ultraviolet radiation can
cause localised immune suppression (Grossman 1997). Human
papillomavirus (HPV) infection is also thought to play a role in skin
cancer carcinogenesis (Karagas 2006)
Normally, the immune system is able to detect early developing
NMSCs and clear them eCectively. Impairment of the immune
system may allow the cancer to develop and prevent it from being
rejected by the body.
High-risk groups
There are subsets of people that are at greater risk of developing
NMSC than the general population. The following is not an all
inclusive list but covers a broad range of key groups as highlighted
from the literature.
i) Individuals with precursor lesions
People with a precursor lesion are at more risk than the general
population of developing a SCC. Not all precursor lesions, however,
develop into SCCs. Only 4 to 6% of Bowen's disease transform to
SCC (Eedy 2000) while the progression rate from AK to SCC ranges
from 0.025% to 20% (Alam 2001).
ii) Individuals with a previous NMSC
The risk of developing a subsequent NMSC in people who have
developed a first NMSC is not well defined. A critical review and
meta-analysis (Marcil 2000) has found that for people with fewer
than 3 previous NMSCs the risk of developing another NMSC within
the following 3 years is 38%. In people with 3 to 9 previous NMSCs
this risk rises to 93%. One study found that individuals with more
than nine prior NMSCs develop a new NMSC within two years (Marcil
2000).
iii) Lowered immunity
People who have had organ transplants (OTs) have a three to
four fold increased risk of developing any cancer, over the general
population. The risk of developing certain malignancies, including
NMSC is dramatically higher in people with OTs. One study suggests
that people who have had renal (kidney) transplants are 500 times
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more likely to develop NMSC than the general population (Hartevelt
1990). In Australia, incidence rates of NMSC in renal transplant
recipients increases exponentially over time: 3% within the first
year, 25% at 5 years and 44% at 9 or more years post transplant
(Hardie 1980). As with the normal population tumour development
is more likely with increased ultraviolet exposure, advancing age
and fair skin.
Some people's immune systems do not function properly (i.e.
they are immunocompromised) due to congenital disorders,
viral infection or AIDS. Basal cell carcinoma is one of the
most frequent malignant tumours among people with acquired
immunodeficiency syndrome (AIDS) and its incidence appears to be
higher than in the general population, although there is not enough
epidemiological data to confirm this (Demopoulos 2003). People
who are human immunodeficiency virus (HIV) positive develop
NMSC at a significantly younger age than people who are HIV
negative (Demopoulos 2003).
iv) Xeroderma pigmentosum
People with the rare inherited genetic (autosomal recessive) skin
disorder, xeroderma pigmentosum (XP), have an abnormality in
the ability to repair UV-induced DNA damage. This results in the
development of a large number of skin cancers from as early
as two years of age. The median age of developing an NMSC
in people with XP is 8 years old, compared to 60 years old in
the general population (Kraemer 1980; Kraemer 1994). People
with XP have over a 100 fold increased incidence of BCC or SCC
than the general population, with 45% of them developing an
NMSC (Kraemer 1980; Kraemer 1994). Photosensitivity begins in
infancy, and freckles and keratoses (rough scaly patches) appear
on exposed skin in childhood. SCCs, BCCs, keratoacanthomas and
malignant melanomas subsequently develop in the UV-damaged
skin.
v) Albinism
Albinism describes people who lack skin pigment and hence the
ability to tan. It is caused by a large group of genetic disorders.
Albinos are at increased risk of all skin cancers especially SCC, since
they lack the protective eCects of melanin in the skin. In a study
of 164 albinos in Tanzania, 91% of those who were over 20 years
of age had AK, rising to 100% of those who were over 30 years old
(Lookingbill 1995).
vi) Trauma and burns
SCC is uncommon in Blacks, Asians and Hispanics, however if
SCCs occur they do so on sites of pre-existing inflammatory skin
conditions, burn injuries, or trauma.
vii) Basal cell naevus syndrome
Basal cell naevus syndrome (also known as Gorlin's syndrome) is
a genetic autosomal dominant condition characterised by a range
of skin and skeletal abnormalities and an increased occurrence
of 2 or more BCC before the age of 30 (Johnson 1996). The
syndrome is caused by mutations in the patched gene, present on
chromosome 9, required for proper embryonic development and
tumour suppression (Johnson 1996).
viii) Exposure to arsenic
Arsenic is the 20th most abundant element and exhibits both acute
and chronic eCects on humans (Neubauer 1947). It is ubiquitous in
soil and is found in high concentrations in water wells in Taiwan,
Argentina, Sweden and other regions where mining and smelting
is prevalent (Neubauer 1947). It is also present in some forms
of traditional Indian medicine and in illegally produced alcoholic
beverages such as moonshine (Hughes 1983; Treleaven 1993). Many
occupations involve exposure to arsenic including the agricultural
industry. Arsenic is a carcinogen that is able to cause cancerous
transformations of mammalian cells under laboratory conditions
(Pershagen 1981). Three cutaneous cancers are associated with
chronic exposure to arsenic: BCC and two precursors of SCC,
Bowen's disease and arsenical keratosis. The distribution of lesions
caused by arsenic exposure is not limited to parts of the body that
have been exposed to sun or x-rays. A scattering of neoplasms
throughout the body are observed with the preferential formation
of arsenical keratoses on the palms. It takes an average of 17.8 years
from initial exposure to arsenic to developing cancer (Schwartz
1997). Chelation therapy, which removes arsenic, is available for
people who have been exposed, however by the time cutaneous
and other cancers develop there are likely to be no traces of arsenic
leM to eliminate (Heyman 1956).
ix) Recessive dystrophic epidermolysis bullosa (RDEB)
RDEB Hallopeau-Siemens (RDEB-HS), the most generalised
subtype of RDEB, is thought to be one of the most devastating,
chronic diseases known to human beings. It is due to an inherited
defect in the type VII collagen gene, whereby there is either
no collagen VII produced or very low levels. Collagen VII forms
anchoring fibrils, crucial structures that "sew" the outer skin
(epidermis) onto the inner skin (dermis). RDEB-HS is characterised
by repeated blister formation, leading to mechanical fragility of
the skin. It can aCect all tissues with an epithelial surface or
lining. People who survive recurrent bacterial sepsis during infancy
are at high-risk of developing severe complications in later life
including renal failure, corneal scarring and blindness, in addition
to the progressive mutilation with eventual loss of their fingers
and toes (Fine 2004) . The most severe complications are SCCs,
which tend to arise within chronically eroded or hyperkeratotic
skin lesions. Approximately 85% of all individuals with RDEB-HS
will have developed one cutaneous SCC by the age of 45 years
and the risk is about 50 times the normal (Fine 1999). It is not yet
understood why these people are at increased risk for SCC, other
than having chronic non-healing wounds for at least 14 years, when
the incidence of SCCs starts to rise.
x) People treated using psoralen and ultraviolet A treatment
(PUVA)
PUVA has been widely used as a treatment for psoriasis and
other skin conditions since 1974 (Parrish 1974). Exposure to PUVA
increases the risk of SCC in a dose dependent manner, while a
substantial increase in the risk of BCC has not been observed
(Stern 1998). In addition to being both mutagenic and carcinogenic
(Dunnick 1991) PUVA is immunosuppressive in the skin. During
active treatment it may therefore increase the risk of skin cancer
in a pattern similar to that observed with people undergoing
immunosuppressive therapy (e.g. transplant recipients). One study
has found that people with at least 337 PUVA treatments had more
than 100 fold increase in the risk of developing SCC, within 10 years
of stopping treatment (Stern 1998), compared with that expected
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from population incidence rates. The risk of developing a SCC in the
second decade aMer cessation of PUVA treatment was 70 fold (Stern
1998).
Clinical Features
BCCs exhibit several markedly diCerent subtypes and occur at
diCerent places on the body (Wong 2003).
Eighty-five percent appear on the head and neck region, while the
rest are observed mainly on the trunk and lower limbs, especially
in women (McCormack 1997).
Subtypes of BCC include:
• superficial, which is a well-demarcated, scaly, red minimally
indurated plaque that can mimic a papulosquamous rash such
as psoriasis• nodular• multifocal• morphoeic (scarring), which is the most invasive type• ulcerated• pigmented, which is oMen confused with melanoma• cystic
Sixty percent of the BCCs diagnosed in the UK are nodular,
presenting as a pearly papule with telangiectasias (raised areas
through which dilated vessels may show) throughout. In other
countries, however, such as Australia, superficial BCC is the most
common type (Staples 1998). Both nodular and superficial BCC
usually exhibit a non infiltrative, superficial growth pattern and
are therefore associated with low risk (Martinez 2001). The most
important subtype clinically is morphoeic BCC, which has a more
aggressive natural history and accounts for approximately 5% of
all lesions (Wong 2003). Since they are diCicult to diagnose, the
tumours can be huge and devastating to the individual. Complete
surgical excision is diCicult under direct vision since morphoeic
BCCs have ill defined borders (Wong 2003), and oMen lengthy
plastic surgical reconstructions are required to correct cosmetic
disfigurement (Wong 2003).
SCCs present clinically as nodular, superficial or as cutaneous horns
(Dinehart 1996). Actinic keratoses (AKs), sometimes a precursor to
SCC, appear as scaly pink patches located on sun exposed areas
and are very common. Over 80% of fair skinned people aged 60 to
69 in the USA have at least one AK (Glass 1989). Most SCCs and AKs
(about 70 to 80%) occur on the head and neck (Glass 1989; Gray
1997; Holme 2000; Iversen 1999). Bowen's disease presents as a
red scaly or crusted plaque containing squamous cells and tends to
be asymptomatic. Bowen's disease can aCect any anatomical site,
including the lower leg in women and the penis in men (Cox 1999).
There is a commonly held impression that SCC is a relatively benign
form of cancer; however, the potential for metastasis can range
from 0.5% to 40% depending on the subtype (Eedy 2000). SCCs
developing from AKs have a 0.5 to 2 % rate of metastasis (Eedy
2000). If SCC evolves from Bowen's disease the metastatic rate soars
to 33% (Cox 1999; Eedy 2000). Mortality due to NMSC is mainly due
to metastasis of SCC to lymph nodes and other internal organs.
NMSC have also been linked to second malignancies. Rosenberg
2004 found that women with a history of NMSC were 2.3 times
more likely to report a history of another cancer, other than NMSC,
compared with women who had no history of NMSC.
Diagnosis
The diagnosis of NMSC involves taking a medical history and
a physical examination (NCCN 2004) where the whole body is
examined for spots, bumps, sores and any other potential signs of
skin cancer. If the physical examination and medical history suggest
the possibility of a NMSC a skin biopsy is performed whereby a
sample of skin is taken for microscopic analysis. Two of the most
commonly used biopsy techniques are shave biopsy and punch
biopsy. Both methods are able to determine the cancer type and
pathological growth pattern.
Description of the intervention
Treatment
There are many options for the treatment of NMSC. These therapies
are covered in two other Cochrane systematic reviews (Bath-Hextall
2004; Westby 2004).
Prevention
Prevention is a major component in the management of NMSC.
Primary prevention
The best way to lower the risk of NMSC is to decrease skin exposure
to sunlight, primarily by avoiding the peak hours of sunlight
and avoiding deliberate sun tanning. Educating people, especially
children, about the dangers of overexposure of their skin to sunlight
is another way to reduce NMSC (Naldi 2004).
Secondary prevention
This has the aim of encouraging people to recognise skin changes
and seek early diagnosis and treatment, as well as improving
eCective diagnosis.
Tertiary prevention
This involves extra interventions aMer treatment to reduce the risk
of re-occurrence or further development of the disease.
A combination of primary, secondary and tertiary prevention is
particularly necessary for individuals who are at high risk of
developing NMSC, as identified earlier.
Sunscreens
Sun protective products include sunscreens and sun blocks.
Sunscreens of a chemical nature, (such as oxybenzone,
avobenzone) work by absorbing UVR. Physical sunscreens contain
titanium dioxide or zinc oxide, which scatter or block UVR. An in
depth review on the use of sunscreens in the prevention of NMSC is
given elsewhere (Gasparro 1998; Naylor 1997).
Retinoids
Retinoids are vitamin A derivatives. Experimental vitamin A
deficiency, leading to cancer in rats, provided some of the
earliest links between vitamin A and malignancies. Early studies,
administering high dose retinoids for treating and preventing skin
cancer in people considered to be at high-risk of BCC, showed
promising results (Peck 1982; Peck 1988). Although only a small
number of studies have been reported, synthetic retinoids have
shown the most promise for preventing NMSC in high-risk groups
such as those with XP (Lippman 1987) and people who have had
renal transplants (Bavinck 1995). Retinoids work by controlling
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growth, death and diCerentiation of human cells. In malignant cell
lines retinoids inhibit cell growth and induce normal diCerentiation
of the cells (Lippman 1987).
Since vitamin A is stored in the liver, high doses may produce
persistent side eCects. Adverse eCects include dryness and
chapping of the lips, mucous membranes and skin in addition
to skeletal toxicities. This has led to the development of
synthetic retinoids, designed to have better therapeutic properties
with lower toxicity. Osteoporosis, calcification of tendons and
ligaments, osteophytes and bone spurs around joints may be
accelerated by long-term retinoid therapy (DiGiovanna 1995;
DiGiovanna 2001).
Antioxidants
i) Selenium
Selenium is an essential trace element found in fish, shellfish
and garlic. It is necessary for the functioning of the detoxifying
enzyme glutathione peroxidase within cells. This enzyme helps
to reduce the presence of highly reactive hydroxyl free radicals
which are thought to attack DNA, inducing mutations (Buettner
1993) and thus its function is essential for a cell to remain damage
free. Studies in mice have shown that increased levels of dietary
selenium provide protection from UV induced skin tumours (Pence
1994).
ii) Beta-carotene
Beta-carotene (ß-carotene) is the best characterised of a large
group of carotenoid pigments that are widely distributed in
vegetables and fruit. Although ß-carotene has pro-vitamin A
(retinol) activity, it is possible that ingestion of ß-carotene
might prevent cancer without the involvement of retinol. It is
an antioxidant that may reduce free radical damage of DNA
aMer ultraviolet exposure. Some studies suggest that ß-carotene
supplementation works by reducing immunosuppression normally
induced by ultraviolet radiation (Fuller 1992).
iii) Vitamin C
Vitamin C (ascorbic acid) is present in citrus fruits and potatoes.
It has been shown that UV exposure in the epidermis and dermis
in mice leads to the depletion of vitamin C (Shindo 1993). Vitamin
C may play a role in preventing skin cancers by scavenging free
radicals in cells, thus protecting the cells from DNA damage.
iv) Vitamin E
Vitamin E (present in vegetable oils, nuts and leafy green
vegetables), like vitamin C, scavenges free radicals and protects
cell membranes from damage. Topical vitamin E in mice has been
shown to prevent UV induced immunosuppression (Gensler 1996),
inhibit UV-induced thymine dimer formation (McVean 1999) and
inhibit absorption of UVB radiation (McVean 1999).
Dietary modifications
Reduction of fat intake
It has been noted that unsaturated fatty acids are a major target for
free radical attack. It is therefore possible that decreased dietary
fats could reduce free radical attack and carcinogenesis (Black
1998).
Complementary therapies
The use of complementary therapies for the treatment of a number
of diseases, including cancer has increased. Their perceived lack
of side eCects has increased their popularity over conventional
synthetic treatments. A literature review is available which outlines
the variety of herbal therapies that have been tested to treat or
prevent NMSC (Bialy 2002). Phytochemicals have been the focus
of many studies in the last decade e.g. tea is thought to act by a
variety of mechanisms to prevent NMSC, including the induction of
apoptosis (cell death) in tumour cells (Alexis 1999).
Alternative immunosuppressive regimens
Reduction of immunosuppressive burden and shiM to alternative
immunosuppressive regimens may represent an option in
transplanted patients with a first skin cancer. This will be covered
in the updated review.
Why it is important to do this review
NMSC are not usually considered life-threatening but they take
a huge toll on health service budgets, as well as contributing to
days lost in the workplace. Prevention is a better option than
cure, especially given that preventative measures have a good
chance of working. Many treatments have been described for the
prevention of NMSC in high-risk groups, but there are no evidence-
based guidelines. Literature reviews exist on the treatment and
prevention of NMSC in the general population in addition to high-
risk groups, however, no systematic reviews exist on the topic.
O B J E C T I V E S
To evaluate interventions for the prevention of NMSC in people at
high-risk of developing NMSC.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of interventions to prevent NMSC in
people at high-risk of developing NMSC. These will include any
relevant study that compares any combination of interventions,
any interventions compared to control (placebo/no treatment), or
diCerent dosages/durations of the same interventions.
Types of participants
Adults and children who are at high risk of developing NMSC. These
are defined as people who:
• have had a previous biopsy proven NMSC (BCC or SCC);• are organ transplant recipients;• have xeroderma pigmentosum;• have Gorlin's syndrome;• have been exposed to high levels of arsenic;• are immunocompromised due to disease (e.g. AIDS);• have albinism;• have precursors to SCC (Bowen's disease, solar keratoses);• are trauma patients (e.g. burns patients, large scars);• have RDEB (recessive dystrophic epidermolysis bullosa);• have been treated using PUVA (psoralen ultra violet A).
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Types of interventions
(1) Topical therapies
(2) Retinoids
(3) Antioxidants• selenium• beta carotene• vitamin C• vitamin E
(4) Dietary modifications• reduction in fat intake
(5) Complementary therapies• phytochemicals e.g. green tea
Types of outcome measures
Primary outcomes
(i) The time from start of prevention to the development of a first
NMSC, or in those with a previous NMSC, the development of a
subsequent NMSC up until a maximum of five years.
• Recurrence may either be a NMSC at another anatomical site or
recurrence at the site of the primary NMSC.
Secondary outcomes
(i) Number of people with a new NMSC at two to five years from the
start of treatment.
(ii) Number of people with a new NMSC within the first year from
the start of treatment.
(iii) Mortality at the end of trial.
(iv) Number of people with other cancers at the end of trial.
(v) Adverse eCects.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Skin Group's Specialised Register (March
2007) using the following search terms:
((non melanoma and skin and cancer) or (basal or squamous
and (cell and carcinoma)) or 'BCC' or 'NMSC' or 'SCC' or (organ
and transplant and recipient) or (xeroderma and pigmentosum) or
(Gorlin* and syndrome) or arsenic or 'AIDS' or immunocompromis*
or albinism or (Bowen* and disease) or (solar and keratos*)
or burn* or scar* or 'RDEB' or (recessive and dystrophic and
epidermolysis and bullosa) or 'PUVA' or (psoralen and ultra and
violet)) AND (sunscreen* or antioxidant* or retinoid* or selenium
or (beta and carotene) or (vitamin and ('A' or 'E')) or (diet* and
(modification* or fat*)) or (complementary and (medicine* or
therap*)) or phytochemical* or (green and tea*) or prevention*)
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 1, 2007) using the search
strategy in Appendix 1.
We searched MEDLINE (OVID) (from 2003 to March 2007) using the
search strategy in Appendix 2.
We searched EMBASE (from 2005 to March 2007) using the search
strategy in Appendix 3.
Searching other resources
Pharmaceutical companies
Pharmaceutical companies were contacted where appropriate for
information about unpublished trials.
Published and unpublished trials
References from included published studies were checked for
further trials. The metaRegister of Controlled Trials, which includes
the NHS Trusts Clinical Trials Register (www.controlled-trials.com),
was searched for ongoing trials (February 2007). Contact was made
with specialists, such as clinicians and academics in the field, for
information about ongoing or unpublished trials.
Language
No language restrictions were imposed and translations were
obtained where necessary.
Adverse E0ects
We looked at adverse events only in the included studies.
Data collection and analysis
Selection of studies
Two authors (FB-H, NS) checked the titles and abstracts identified
from the searches. The same two authors independently assessed
the full text of all RCTs of possible relevance and decided on which
trials fitted the inclusion criteria. Any disagreements were resolved
by discussion between the authors. We contacted trial authors for
clarification where ambiguities existed
Data extraction and management
Two authors (FB-H, JL-B) independantly performed data extraction,
using a specially designed data extraction form, and discrepancies
were resolved by a third author (AW or WP). Missing data were
obtained from the trial authors where possible. One author (FB-
H) entered data into RevMan and this was double checked by
JL-B. Data recorded included: demographics, sites, clinical types,
histological diagnosis, follow up period, number of previous NMSC
and how they were treated, skin tone and loss to follow-up, country
of residence.
Assessment of risk of bias in included studies
The quality assessment included an evaluation of the following
components for each included study, since there is some evidence
that these are associated with biased estimates of treatment eCect
(Juni 2001):
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it will be considered
'adequate' if the assignment cannot be foreseen;
(c) who was blinded/ not blinded (participants clinicians, outcome
assessors);
(d) how many participants were lost to follow up in each arm and
whether participants were analysed in the groups to which they
were originally randomised (intention to treat).
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The information was recorded in a table of quality criteria (Table 1)
and a description of the quality of each study was given based on
these components.
Measures of treatment e<ect
We calculated a weighted pooled treatment eCect across studies
using a random eCects model. We expressed the results as risk
ratio (RR and 95% confidence intervals (CI) for dichotomous
outcomes due to non rare expected events, and mean diCerence
(MD and 95% CI) for continuous outcomes. The hazard ratio
and associated statistics were calculated, where necessary, using
and Excel spreadsheet developed by the Matthew Sydes (Cancer
Division) in collaboration with the Meta-analysis Group of the MRC
Clinical Trials Unit, London.
Unit of analysis issues
Cross-over studies were analysed using methods appropriate for
such studies. We expressed the results as number needed to treat
(NNT), where appropriate, with a 95% CI and the baseline risk to
which it applies.
Assessment of heterogeneity
Heterogeneity in studies was explored using I2.
Subgroup analysis and investigation of heterogeneity
Where substantial heterogeneity existed between studies for the
primary outcome (I2 > 50%) , we planned sensitivity analyses to
examine the eCects of excluding study subgroups, e.g. those studies
with lower reported methodological quality (i.e. studies that did
not clearly report randomisation, blinding and which do not have
an 'intention to treat' analysis'), however the insuCicient number
of studies available precluded this. Where data were available, we
performed a subgroup analysis if appropriate for BCCs versus SCCs.
Other
A consumer was consulted throughout, particularly for readability
and understanding of the final review.
R E S U L T S
Description of studies
Results of the search
We identified 10 fully published studies (7,229 participants). Three
of the authors ( FB-H, JL-B, NS) independantly examined the full
text of each study. All the studies were parallel group studies
with the exception of one cross over study (George 2002). See
'Characteristics of included studies'. Seven of the studies were
conducted in the USA (Black 1995; Clark 1996; Greenberg 1990;
Levine 1997; Moon 1997; Tangrea 1992; Yarosh 2001). Two of the
studies were conducted in the Netherlands (Bouwes Bavinck 1995;
de Sevaux 2003), one in Australia (George 2002). Eight studies
were multicentre and two were single centres (Black 1995; de
Sevaux 2003). Only one study was conducted on participants with
Xeroderma pigmentosum (Yarosh 2001), two studies included renal
transplant recipients( RTR) and seven were on people with previous
NMSC or precursors. In only one of the studies were the participants
children (Yarosh 2001).
Included studies
(1) Topical therapies
One study was included.
T4N5 liposome
T4N5 liposome lotion contains the bacterial enzyme T4
endonuclease V encapsulated in a pH sensitive engineered
liposome for delivery into the living cells of the skin. These
liposomes are applied in a hydrogel lotion.
T4N5 liposome lotion vs placebo (Yarosh 2001)
(2) Retinoids
Six studies were included:
• acitretin vs placebo (Bouwes Bavinck 1995);• acitretin 0.4 mg/Kg/d for 1 yr vs 0.4 mg/Kg/d for 3 months then
0.2 mg/Kg/d of 9 months vs placebo (de Sevaux 2003);• acitretin vs placebo (cross-over study) (George 2002);• oral retinol vs oral isotretinoin vs placebo (Levine 1997);• oral retinol vs placebo (Moon 1997);• oral isotretinoin vs placebo (Tangrea 1992).
(3) Antioxidants - two studies
Selenium
Oral selenium vs placebo (Clark 1996).
Beta carotene
Beta carotene vs placebo (Greenberg 1990).
(4) Dietary modifications -one study
Reduction of fat in diet vs normal diet (Black 1995).
(5) Complementary therapies
No studies of complementary therapies were identified.
Excluded studies
Seven studies were excluded see Characteristics of excluded
studies.
Risk of bias in included studies
Allocation
Nine of the studies were randomised controlled, parallel design and
one was a randomised controlled cross-over design (George 2002).
The randomisation process in general and concealment of
allocation in particular are the most important and sensitive
indicators that bias has been minimised in a clinical trial (Schulz
1995). Only five of the ten studies showed both clear randomisation
and concealment of allocation ( Tangrea 1992; Yarosh 2001;
Greenberg 1990; Clark 1996; Bouwes Bavinck 1995). However eight
of the studies clearly described the method of randomisation.
Blinding
Only one study blinded participants, clinicians and outcome
assessors (Yarosh 2001). Five studies blinded participants and
clinicians (Clark 1996; Bouwes Bavinck 1995; Greenberg 1990;
Levine 1997; Tangrea 1992). One study blinded the outcome
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assessor and participant (Moon 1997). In one study the blinding
was unclear (de Sevaux 2003) and in another study there was no
blinding (George 2002).
Incomplete outcome data
Handling of losses and attrition bias
Analysis should be performed according to intention-to-treat
principle, thus avoiding bias (Altman 1991; May 1981; Sackett 1979).
However, in three of the studies analysis of outcome was carried
out only in those participants who completed the study (Black 1995;
Bouwes Bavinck 1995; Yarosh 2001).
Other potential sources of bias
Baseline comparability of the participants for age, sex
For all studies the baseline diCerences were comparable between
the treatment groups.
E<ects of interventions
(1) Topical therapies
Only one study (Yarosh 2001) was identified that compared
T4N5 liposome lotion vs placebo in 30 children and adults with
xeroderma pigmentosum over a period of a year .
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
No data available
(ii) Recurrence
No data available
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
No data available
(ii) Number of people with new NMSCs within the first year from the
start of treatment
The study reported significantly fewer BCCs per year (mean
diCerence 1.6 per year) in the treatment group (T4N5) as compared
to the placebo group, (lesions/year MD -1.6, 95% CI -2.8 to -0.40;
Analysis 1.4). There was no significant diCerence in the risk of
getting a NMSC in the treatment group compared to placebo at the
end of first year (RR 0.75, 95% CI 0.4 to 1.42; Analysis 1.1) , however
there was a trend towards a significant 47% reduction in the risk of a
new BCC, (RR 0.53, 95% CI 0.25 to 1.12; Analysis 1.2), p = 0.09. There
was no significant diCerence in risk of a new SCC in the treatment
group compared to the placebo group within the first year (RR 1.35,
95% CI 0.34 to 5.44; Analysis 1.3).
(iii) Mortality at the end of trial follow up
No deaths were reported in either groups at end of study
(iv) Number of people with other cancers at the end of trial follow up
There were no significant diCerences in numbers of other cancers
(RR 1.13, 95% CI 0.27 to 4.74; Analysis 1.5).
(v) Adverse e<ects
No information was given on adverse events.
(2) Retinoids Acitretin versus placebo
Two studies compared acitretin versus placebo (one parallel study
and one cross-over) and one study compared two diCerent doses of
acitretin. All were conducted in renal transplant recipients (RTRs).
The first study (Bouwes Bavinck 1995) compared 30mg/d of oral
acitretin to placebo in 115 RTRs over 6 months.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
There were no significant diCerences in time to developing a new
NMSC between the treatment groups within the first 6 months (HR
0.51, 95% CI 0.07 to 3.55; Analysis 2.1)
(ii) Recurrence
No data available
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
No data available
(ii) Number of people with new NMSCs within the first year from the
start of treatment
A 78% significant reduction in the risk of NMSC was seen in the
participants in the acitretin group as compared to placebo within
first year (RR 0.22, 95% CI 0.06 to 0.90; Analysis 2.4).
(iii) Mortality at the end of trial follow up
No data on deaths were reported
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
There were no significant diCerences in risk of adverse events (RR
1.10, 95% CI 0.07 to 16.43; Analysis 2.9)
In a second study 23 participants were included in a two-period
crossover design of acitretin (25 mg/day) versus placebo (George
2002). It was not possible to extract data for many of the outcomes
of interest.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
No data available
(i) Recurrence
No data available
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
No data available
Interventions for preventing non-melanoma skin cancers in high-risk groups (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
(ii) Number of people with new NMSCs within the first year from the
start of treatment
No data available
(iii) Mortality at the end of trial follow up
No data available
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
There was no significant reduction in risk of adverse events in the
placebo group compared to the treatment group (RR 1.93, 95% CI
0.71 to 5.26; Analysis 2.9).
Pooled data from two studies (Bouwes Bavinck 1995; George 2002)
suggested no significant diCerence in the risk of adverse events in
the acitretin group when compared to placebo (RR 1.80, 95% CI 0.70
to 4.61; Analysis 2.9). No heterogeneity was seen between the trial
estimates (I2=0%).
A third study in 26 RTRs compared 0.4 mg/Kg/d acitretin for 12
months versus 0.4 mg/Kg/d for 3 months then 0.2 mg/Kg/d for 9
months (de Sevaux 2003).
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
No data available
(ii) Recurrence
No data available
(b) Secondary outcomes
Only overall numbers of new NMSC were given but no numbers for
individual treatment groups.
(i) Number of people with a new NMSCs at two to five years from the
start of treatment
No data available
(ii) Number of people with a new NMSCs within the first year from the
start of treatment
No data available
(iii) Mortality at the end of trial follow up
No data available
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
There was no significant diCerence in risk of adverse events in the
higher dose group as compared to the lower dose group, (RR 0.34,
95% CI 0.08 to 1.46; Analysis 4.1).
(2) Retinoids (B) Retinol versus placebo
Two studies compared retinol versus placebo (Levine 1997; Moon
1997) in people with a history of NMSC.
The first study (Moon 1997) compared oral retinol to placebo in 2297
adults over 5 years.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
Retinol significantly reduced time to a first new SCC by 26% as
compared to placebo (HR 0.74, 95% CI 0.55 to 0.99; Analysis
2.3). However, there was no significant diCerence in the risk of
developing a new BCC (HR1.06, 95% CI 0.85 to 1.32; Analysis 2.2).
(b) Secondary outcomes
(i) Number of people with a new NMSCs at two to five years from the
start of treatment
There was no significant diCerence in number of SCCs at two to five
years from the start of the prevention (RR 0.82, 95% CI 0.65 to 1.04;
Analysis 2.8)
(ii) Number of people with a new NMSCs within the first year from the
start of treatment
No data available
(iii) Mortality at the end of trial follow up
No significant diCerence in mortality at end of trial (RR 1.15, 95% CI
0.81 to 1.65; Analysis 2.10)
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No significant diCerence in adverse events at the end of the study
(RR 1.12, 95% CI 0.88 to 1.42; Analysis 2.9).
The second study compared retinol, isotretinoin and placebo, in
525 adults over 3 years (Levine 1997).
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
There was no significant diCerence in the time to the development
of a new BCC in the retinol group as compared to placebo (HR 1.08,
95% CI 0.86 to 1.36; Analysis 2.2) or SCC (HR 1.21, 95% CI 0.78 to
1.87; Analysis 2.3), respectively
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
There were no significant diCerence in the number of new BCCs at
two to five years (RR 1.05, 95% CI 0.91 to 1.22 ; Analysis 2.7).There
was no significant diCerence in number of people with SCC at two
to five years RR 1.27, 95% CI 0.88 to 1.84; Analysis 2.8).
(ii) Number of people with new NMSCs within the first year from the
start of treatment
There was no significant diCerence in number of new BCCs within
the first year when retinol was compared to placebo (RR 1.12, 95%
CI 0.88 to 1.43; Analysis 2.5). There was a trend towards fewer
number of people with SCC in the placebo group compared to
retinol group within the first year, (RR 1.53, 95% CI 0.92 to 2.55, p =
0.1, Analysis 2.6)
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(iii) Mortality at the end of trial follow up
No data available
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No data available
In a pooled analysis of the two trials there was no significant
diCerence in the time to a new BCC or SCC when retinol was
compared to placebo (pooled data: HR 1.07, 95% CI 0.91 to
1.25; Analysis 2.2; and HR 0.92, 95% CI 0.57 to 1.49; Analysis 2.3
respectively). High levels of heterogeneity were seen between the
two trials (I2 = 70.6%).
In a pooled analysis, no significant diCerence in risk was seen for the
number of people with a new SCC at two to five years from the start
of prevention treatment (RR 1.00, 95% CI 0.65 to 1.53, Analysis 2.8)
when retinol was compared to placebo. High levels of heterogeneity
were also seen between the trial results for this comparison (I2 =
74.2%).
(2) Retinoids (C) Isotretinoin versus placebo
Two studies compared isotretinoin versus placebo (Levine 1997;
Tangrea 1992) in people with a history of NMSC - the second study is
also covered under retinols versus placebo. The first study (Tangrea
1992) compared isotretinoin versus placebo in 981 participants
over 3 years and followed-up for a further 3 years.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
There was no significant diCerence in time to a new BCC in
participants receiving isotretinoin and those receiving placebo (HR
1.02, 95% CI 0.89 to 1.17; Analysis 2.2).
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
No significant diCerence in the number of people with a new BCC
at two to five years from start of prevention (RR 1.00, 95% CI 0.92 to
1.08; Analysis 2.7).
(ii) Number of people with new NMSCs within the first year from the
start of treatment
No significant diCerences in the number of people with a new BCC
in first year (RR 0.93, 95% CI 0.82 to 1.07; Analysis 2.5).
(iii) Mortality at the end of trial follow up
No data available
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
Significantly more adverse events were reported in the isotretinoin
group as compared to placebo (RR 1.76, 95% CI 1.57 to 1.97; Analysis
2.9). Most of the adverse events were mucocutaneous.
The second study (Levine 1997) compared retinol, isotretinoin and
placebo in 525 participants over 3 years.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
Participants in the isotretinoin group were 79% significantly more
likely to develop a new SCC during the trial (HR 1.79, 95% CI 1.16
to 2.76; Analysis 2.3) compared to the placebo group. However,
there was no significant diCerence in time to developing a new BCC
between the isotretinoin and placebo groups (HR 1.00, 95% CI 0.79
to 1.26; Analysis 2.2).
(b) Secondary outcomes
(i) Number of people with new NMSCs at two to five years from the
start of treatment
There was no significant diCerences in the number of people with a
new BCC (RR 1.00, 95% CI 0.86 to 1.17; Analysis 2.7) or SCC (RR 1.16,
95% CI 0.79 to 1.69; Analysis 2.8) between two to five years from
start of prevention.
(ii) Number of people with new NMSCs within the first year from the
start of treatment
There was no significant diCerence in the number of participants
with a new BCC or SCC within the first year from start of prevention
(RR 0.94, 95% CI 0.72 to 1.22, Analysis 2.5; RR 0.88, 95% CI 0.49 to
1.59; Analysis 2.6, respectively).
(iii) Mortality at the end of trial follow up
No data available
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No data available since numbers cannot be added up i.e. one
participant may experience more than one event.
In a pooled analysis of the two trials which assessed isotretinoin
as compared to placebo (Levine 1997; Tangrea 1992), no significant
diCerences were seen for the time to a new BCC (HR 1.01, 95% CI
0.90 to 1.14; Analysis 2.2), the number of people with a new BCC
within the first year (RR 0.93, 95% CI 0.83 to 1.05, Analysis 2.5) or two
to five years (RR 1.00, 95% CI 0.93 to1.08; Analysis 2.7) from start of
prevention.
(3) Antioxidants (A) Selenium vs placebo
Only one study was identified (Clark 1996) which was conducted
in people with a history of NMSC and a second paper by (DuCield-
Lillico) gave further follow up data on secondary outcomes. This
study compared oral administration of 200 ug/day of selenium to
placebo in 1312 participants for a mean of 4.5 years.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
Participants in the selenium group were 17% more likely to develop
a new NMSC during the trial (HR 1.17, 95% CI 1.02 to 1.34; Analysis
3.1) and this was statistically significant and appeared to be
primarily related to the development of SCCs (HR 1.25, 95% CI 1.03
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to 1.51; Analysis 3.3) rather than the development of BCCs (HR 1.09,
95% CI 0.94 to 1.26; Analysis 3.2).
Secondary outcomes
(a) Number of people with new NMSCs at two to five years from the
start of treatment
There was no significant diCerence in number of people with a new
BCC or SCC two to five years from start of prevention treatment
in the selenium group as compared to placebo (RR 1.09, 95% CI
0.99 to 1.20, Analysis 3.6; RR 1.16, 95% CI 0.99 to 1.36, Analysis 3.7,
respectively).
(ii) Number of people with new NMSCs within the first year from the
start of treatment
No data available
(iii) Mortality at the end of trial follow up
No significant diCerence in mortality at end of trial (RR 0.84, 95% CI
0.67 to 1.07; Analysis 3.10).
iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No significant diCerences in the risk of adverse events (RR 1.51, 95%
CI 0.78 to 2.95; Analysis 3.9) or mortality at the end of trial (RR 0.84,
95% CI 0.67 to 1.07; Analysis 3.10). A 35% significant reduction in the
risk of other cancers was seen in the selenium group as compared
to the placebo group at the end of the trial (RR 0.65, 95% CI 0.50 to
0.85; Analysis 3.8).
(3) Antioxidants (B) Beta carotene vs placebo
Only one study was identified (Greenberg 1990) which assessed the
treatment in people with a history of NMSC. This study compared 50
mg beta carotene versus placebo over 5 years in 1805 participants.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
There was no significant diCerence in time to a new NMSC (HR
1.03,95% CI 0.90 to1.18; Analysis 3.1)
Secondary outcomes
(i) Number of people with a new NMSCs at two to five years from the
start of treatment
There was no significant diCerence in number of participants with a
new NMSC at two to five years (RR 1.04, 95% CI 0.93 to 1.17; Analysis
3.5), number of new BCCs (RR 1.03, 95% CI 0.91 to 1.16; Analysis 3.6)
or SCCs (RR 1.21, 95% CI 0.87 to 1.68; Analysis 3.7).
(ii) Number of people with a new NMSCs within the first year from the
start of treatment
There was no significant diCerence in the number of participants
with a new NMSC in first year (RR 1.03, 95% CI 0.84 to 1.27; Analysis
3.4)
(iii) Mortality at the end of trial follow up
No significant diCerence in mortality at the end of trial (RR 1.07, 95%
CI 0.79 to 1.46; Analysis 3.10)
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No data available
(4) Dietary modifications
Only one study was identified (Black 1995) which assessed the
treatment in people with a history of NMSC.
One study compared a diet of reduced fat to a normal diet over 24
months in 115 adults with a history of NMSC. In a separate paper
the authors (Jaax 1997) compare the rate of occurrence of NMSC by
dividing the study into 8 month periods. The results of this paper
are highlighted in the discussion.
(a) Primary outcome
(i) Time from start of prevention to the development of a first NMSC
No data were available for the primary outcome.
(b) Secondary outcomes
(i) Number of people with a new NMSCs at two to five years from the
start of treatment
There was a trend towards a significant reduction in number of
people with a new NMSC at two to five years (RR 0.16, 95% CI 0.02
to 1.31, p=0.09; Analysis 5.2).
(ii) Number of people with a new NMSCs within the first year from the
start of treatment
There were no significant diCerences in number of people with a
new NMSC in the first year (RR 1.31, 95% CI 0.49 to 3.50; Analysis 5.1)
(iii) Mortality at the end of trial follow up
No significant diCerences in risk of mortality were seen between the
reduced fat and normal diets at the end of the trial (RR 0.49, 95% CI
0.05 to 5.27; Analysis 5.3).
(iv) Number of people with other cancers at the end of trial follow up
No data available
(v) Adverse e<ects
No data available
D I S C U S S I O N
Summary of main results
The studies identified in this review fell into three main categories
of people who are at a high risk of NMSC. These were people with
Xeroderma pigmentosum, renal transplant recipients and people
with a history of NMSC. The conclusions from the review are
presented based on these high risk groups.
People with Xeroderma pigmentosum
One study, of good methodological quality (Yarosh 2001) found that
topical application of T4N5 liposome lotion significantly reduced
the rate of appearance of new BCCs and there was a trend for
reducing the risk of getting a new BCC in the treatment group
compared to placebo.
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Renal transplant recipients (RTRs)
Three studies included RTRs and these were found to be of very
diCerent methodological quality. Two studies were of acitretin
versus placebo and one study compared high and low doses of
acitretin. Only one study (Bouwes Bavinck 1995) assessed the
primary outcome of the review but found no significant diCerence
in time to developing a new NMSC in either the acitretin group
or the placebo group within the first six months of prevention
treatment. Pooled data from the two studies (Bouwes Bavinck
1995; George 2002) found no significant diCerence in adverse
events in the acitretin group compared to the placebo group,
and one study (de Sevaux 2003) found no significant diCerence in
adverse events when lower dose acitretin group was compared to
the higher dose group.
People with a history of NMSC
Several RCTs of preventive treatments for people with a history of
NMSC have been conducted; these include retinols, isotretinoin,
selenium, beta carotene, and a low fat diet.
Two studies of retinol included participants with a history of NMSC
(Levine 1997; Moon 1997). Although one of the studies (Moon 1997)
found that retinol significantly reduced the risk of a first new SCC
compared to placebo, pooled data from both studies (Levine 1997;
Moon 1997) showed no significant diCerence in time to first SCC or
BCC. Heterogeneity between the two studies was detected, which
could possibly be due to the poorer quality of the Levine study
as compared to the Moon study. Only one of the studies (Moon
1997) reported adverse events and death data, however there were
no statistically significant diCerences in the risks of these two
outcomes between the treatment groups.
Two studies (Levine 1997; Tangrea 1992) compared isotretinoin
versus placebo and included participants with a history of previous
NMSC. The methodological quality of one of the studies was very
good (Tangrea 1992) and the other was categorised as poorer
quality (Levine 1997). Although pooled data from the two trials
suggested no significant diCerence in time to a new BCC or the
risk of a new BCC, the trial by Levine 1997 found that there was
an increased risk in the time to a new SCC in the isotretinoin
group as compared to the placebo group. One of the studies
reported a significant increase in the risk of adverse events in
the isotretinoin group compared to placebo. When comparing
numbers of participants with new NMSC in the respective groups
between the first and last month periods, it should be noted that
noncompliance in a large percentage of participants enrolled in
retinol chemoprevention studies has been attributed to symptoms
associated with vitamin A ingestion (Cartmel 2000)
One good quality study assessed the eCect of selenium as
compared to placebo in participants with a history of NMSC (Clark
1996). There was a significant increased risk of a new NMSC in
participants in the treatment group and this seemed to be primarily
related to the development of SCCs in particular. Additionally,
selenium was also associated with significantly fewer participants
in the treatment group developing other cancers at the end of the
study. There were no significant diCerences in adverse events.
One good quality study assessed the eCects of beta carotene as
compared to placebo in people with a history of NMSC (Greenberg
1990). They found no significant diCerence in the number of
participants with a new NMSC in first year or at two to five years
from the start of the prevention treatment. Additionally, when
the analysis was grouped into the type of NMSC, no significant
diCerences were seen in the number of new SCCs or BCCs.
Reassuringly, no significant diCerence was seen in the risk of death
at the end of the study.
Only one study was identified which compared a diet of reduced fat
and a normal diet over 24 months in 115 people with a history of
no more than 2 previous NMSC (Black 1995). Very little data were
available from this study for the outcomes of the review. A diet of
reduced fat did not significantly aCect the number of NMSCs in the
first year as compared to placebo; however there were fewer skin
cancers in the reduced fat diet group at the end of the study. There
was no significant diCerence in the risk of death at the end of trial. In
an additional paper the authors divided the study into eight month
periods and when they compared numbers of patients with new
NMSC in the respective groups between the first and last month
periods they found a significant improvement in the low-fat diet
compared to the normal diet (Jaax 1997) .
A U T H O R S '   C O N C L U S I O N S
Implications for practice
It should be borne in mind that reduction in sun exposure through
seeking shade, clothing protection and wearing sunscreens are all
of key importance in the prevention of non melanoma skin cancer.
Sun avoidance and protection are not part of the scope of this
review as they have been considered elsewhere.
Xeroderma pigmentosum is a rare inherited genetic skin disorder.
The frequency of all forms of skin cancer is higher in these people
than in the general population. Topical application of T4N5 appears
to significantly reduce the rate of appearance of new BCCs and
possibly the risk of new BCCs. However these results should not be
taken in isolation since this is based on one small study.
Renal transplant recipients are at a significantly increased
risk of developing skin cancer compared to immunocompetent
individuals. The number of solid organ transplants continue to rise
and survival time continues to improve; however with increased
survival times comes an increased risk of developing skin cancer.
One study (Bouwes Bavinck 1995) found significantly fewer
participants in the acitretin group developed NMSCs within six
months, however this is based on one small study. It is possible that
altering the immunosuppresive regimens may have an important
eCect in reducing NMSC risk and this aspect will be considered in
the next update of this review.
People with a history of NMSC are at increased risk of developing
further NMSC. There is insuCicient evidence to support the use of
retinol however only two small studies have been done. Isotretinoin
increases the risk of developing a new SCC. No diCerence in the
eCectiveness of beta carotene, selenium or a reduced fat diet have
been seen in this review, however data are from single studies.
Implications for research
There is an urgent need for more research since the incidence of
NMSC is increasing year on year and the number of transplant
recipients is also on the increase. Prevention of skin cancers in
these groups should be a priority, not only from the patient
perspective, but also in terms of financial savings for the
Interventions for preventing non-melanoma skin cancers in high-risk groups (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
13
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Health Services. Further randomised controlled studies of the
interventions identified in this review should be done. Further
research in people with Xeroderma pigmentosum is needed since
this disorder of the skin has a huge impact on the quality of life
of these oMen very young people whose life expectancy may be
shortened by over 30 yrs.
Additionally, this systematic review identified no randomised
controlled trials for the prevention of non melanoma skin cancer
for people with albinism; people with trauma or burns; people with
basal cell naevus syndrome; people exposed to arsenic; people with
RDEB; or those treated using PUVA. All of these groups of people are
at a high risk of NMSC and therefore high quality trials of prevention
treatment should be implemented.
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Characteristics of included studies [ordered by study ID]
 
Methods D: parallel group, single centre, USA
AC: unclear
RS: list of randomly generated numbers
B: outcome assessor
PP
Participants Inc: participants with max of two previously pathologically proven NMSCs
Excl: Asian, black, Hispanic or American Indian; genetically predisposed to skin cancer; > two previous
skin cancers; cancer; received photochemotherapy for psoriasis within past five yrs; treatment with an-
timetabolites, systemic glucocorticoid, tretinoin or isotretinoin;received X-ray treatment for acne; tak-
ing megavitamin or mineral supplements; eating therapeutic diet requiring fat intake > 20% of total
calories; diabetic.
Age mean/SD: (T1:51+-9, T2:54+-13)
Duration: two years
Randomised: 115
m/f: (T1: 30/21, T2:36/14)
Black 1995 
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Evaluable: 101
Interventions T1: reduction of fat in diet to 20% of caloric intake through 8 week nutrition classes, T2: continue with
normal diet.
Outcomes FU: four month intervals for two year period.
Number of new confirmed skin cancers per participant totalled at eight month interval over two year
study period.
Notes 14 participants lost to FU (T1:7,T2:7), including 3 deaths (T1:1,T2:2), 4 withdrawals due to illness or hos-
pitalisation (T1:3, T2:1), relocation (T2:2) failure to attend hospital visits (T1:3,T2:2)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk B - Unclear
Black 1995  (Continued)
 
 
Methods D: parallel group, multicentre, Netherlands.
AC: list provided by pharmaceutical company
RS: Randomisation list provided by pharmaceutical company. Participants grouped in blocks of six.
Participants were stratified according to presence or absence of a history of SCCor BCC or both
B: participants, clinicians, outcome assessor.
PP
Participants Incl: renal transplant recipients with at least ten keratotic skin lesions localised on the forearms and
hands.
Excl: creatine clearance < 20 mL/min, serum cholesterol > 9 mmol/L, serum triglyceride > 10 mmol/L,
disturbed liver function, women wanting to bear children.
Set: Netherlands.
Mean age T1: 52.5, T2: 50.6
Randomised: 44
Evaluable: 38
m/f: 23/15
T1: 19, T2: 19
Interventions T1: 30 mg/d oral acitretin for 6 months
T2: placebo for six months
Outcomes FU: month 1,2,3,4.5,6 during tx.
Skin was checked for SCC and BCC all lesions had to be histologically confirmed. Number of keratotic
lesions counted.
Side effects - measurement of 24 hr urinary creatinine clearance every 3 months, serum creatinine,
cholesterol and triglyceride levels and liver function every FU visit.
Notes Withdrawn:
6 - before first FU (T1:2, T2:4)
1 - CVA due to benign tumour (T1)
1- palpitations (T24 - no reason given (T1:1,T2:3)
Risk of bias
Bias Authors' judgement Support for judgement
Bouwes Bavinck 1995 
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Allocation concealment
(selection bias)
Low risk A - Adequate
Bouwes Bavinck 1995  (Continued)
 
 
Methods D: Parallel group, multicentre, (USA)
AC: treatment group assignment made centrally using sealed pill bottles distributed at the clinic
RS: blocked on time and stratified on clinic
ITT
Participants Inc: history of two or more BCCs or one SCC of the skin with one of these carcinomas occurring within
the prior year. Excl: history of sig liver or kidney disease. T1: 653, T2: 659.
Mean age (SD), T1: 63.4 (10.2), T2: 63 (10).
Randomised 1312 from 1983 to 1990 and were followed with regular dermatologic examinations
through, 1993 for a total of 8269 person-years of observation. At end of study period (1993) 43.6% of
participants were still on treatment. Range of active treatment was 0 to 10.3 yrs.
Evaluable: 1303
Interventions T1: 200ug oral selenium, daily in capsule. T2: placebo identical in appearance.
Outcomes Fu: 0,6,12,18,24,30,36,42,48,53 months. Participants were treated for a mean (SD) of 4.5 (2.8) yrs and
had a total FU of 6.4 (2) years. Primary outcome was incidence of BCC and SCC. Secondary outcomes
were all cause mortality and total cancer mortality.
Notes 82% of participants in both groups had missed taking a pill less than twice a month. Thirty-five partici-
pants experienced adverse side effects (mainly gastrointestinal upset) and withdrew (T1:21, T2:14). All
cause mortality (T1: 108, T2: 129).
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Clark 1996 
 
 
Methods D: parallel, single centre, Netherlands.
AC: unclear
RS: sealed envelope with lowest available study number
B: outcome assessor unclear
ITT
Participants Inc: RTR with history of at least one SCC and > ten AKs, of which one was histologically proven.
Excl: participants with nephrotic syndrome, hypercholesterolemia , hypertriglyceridemia, elevated
transaminase levels, excessive alcohol intake; who were pregnant or wishing to become pregnant; us-
ing antiepileptic drugs. No oral retinoids were allowed for one yr before study.
Set:
Mean age T1: 54+-11, T2: 57+-8
Duration:
Randomised: T1: 14, T2: 12
m/f: T1: 8/6; T2: 5/7
Evaluable: 24
de Sevaux 2003 
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Interventions T1: acitretin 0.4 mg/kg/d for 1 yr
T2: acitretin 0.4 mg/kg/d for 3 months then 0.2 mg/kg/d for 9 months.
Outcomes FU: week 2; months 1,2,3,4,5,6,9 and 12. Number of new NMSC compared with total number of tumours
in the 12 months before acitretin treatment.
Notes Two participants discontinued acitretin (T1:1, T2:1) due to adverse events. Treatment dose was low-
ered for five patients (T1: 1, T2:4) in 4 of them due to mucocutaneous side effects.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk B - Unclear
de Sevaux 2003  (Continued)
 
 
Methods D: cross over , multicentre, Australia.
AC: unclear
RS: unclear
B: unclear
ITT
Participants Inc: RTR participants with > three SCC pr BCC in previous five yrs or > ten AKs
Excl: cholesterol > 7 mmol/L, triglyceride > 3 mmol/L, normal liver function, > 10 g of alcohol /day, preg-
nant.
Set:
Mean Age (SD): T1: 56.7(9.5), T2: 52.2(0.2)
Duration: two yrs
Randomisation:
23 participants
m/f: T1: 11/3, T2: 7/2
Evaluable: 23
Interventions T1: acitretin in first year then none, T2: none in first year then acitretin in second year.
Outcomes Fu: weeks 2,4,8,12; then 3 monthly until end of study period. Participants on drug free period followed
up every 12 weeks using same protocol.
Notes withdrawn: nine participants due to side effects.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk B - Unclear
George 2002 
 
 
Methods D:Parallel, Multicentre, USA
AC: participants assigned to treatment by computer
RS: randomisation in blocks of 16 with no stratification
Greenberg 1990 
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B: patient and physician
ITT
Participants 1805 participants
Incl: at least 1 biopsy proven SCC. Excl: xeroderma pigmentosum, basal cell nevus syndrome, cancer
other than skin, liver disease. Age <65 yrs (T1:472, T2:457), >65 yrs (T1:441, T2:435). Previous skin can-
cers 1-3 (T1:688, T2:691), 4-5(T1:106, T2:92), 6-9 (T1:62,T2:54), >10 (T1:51,T2:51).
Randomised: 1805
Evaluable: 1805
Interventions T1:50mg oral B carotene capsule daily, T2: placebo identical in appearance. Duration of treatment five
yrs
Outcomes FU: 4 monthly questionnaire by post, 12 monthly visits to clinic over a 5 yr period. Outcome - occur-
rence of new BCC or SCC.
Notes 271 lost to FU (T1:93, T2:178). 151 deaths (T1:79, T2:72). 80 participants treatment was stopped or al-
tered due to adverse effects (T1: 49, T2:31).
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Greenberg 1990  (Continued)
 
 
Methods D: three arms, multicentre, USA.
AC: unclear
RS: unclear
B: physician and patient
ITT
Participants 525 participants Incl: history of 4 or more pathologically confirmed BCCs or SCCs.
Exc: xeroderma pigmentosum, basal cell naevus syndrome, abnormal liver function.
Age < 66 yrs (T1:76, T2:75, T3:87), age > 66 yrs (T1:97, T2:103, T3:87).
4 to 10 previous NMSC (T1:118, T2:116, T3:113), >10 prior NMSC (T1:47, T2:49, T3:55).
Randomised: 525
Evaluable: 525
Interventions T1: 25000 IU oral retinol (capsule) daily, T2: 10 mg oral isotretinoin (capsule) daily, T3: placebo capsule
identical in appearance. Duration of treatment three yrs
Outcomes FU: at one month and then every 6 months for 3 yrs. Outcomes: time to first BCC or SCC
Notes No loss to FU.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk B - Unclear
Levine 1997 
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Methods D: parallel group, multicentre, USA.
AC: unclear
RS: randomised by permuted blocks of size 4.
B: participants, outcome assessor
ITT
Participants 2297 participants. Incl: history of > ten AKs and at most two SCC or BCCs.
Excl: xeroderma pigmentosum or basal cell nevus syndrome.
Set: USA
Age < 63 T1: 584, T2: 558
Age > 63 T1: 573, T2: 582
Randomised: T1: 1157, T2: 1140.
m/f , T1: 823/334
T2: 795/345
Evaluable:
Interventions T1: 25,000IU oral retinol daily in capsule.
T1: placebo capsule identical in appearance. Duration of treatment five yrs.
Outcomes FU: month 1 and then every 6 months while on treatment (5 yrs). No FU after cessation of treatment. 
Time to first new occurrence of SCC and time to first new occurrence of BCC
Notes 334 participants lost to Fu (T1:169,T2:165). 239 participants withdrew from trial due to adverse effects
(T1: 127, T2:112). 115 deaths (T1:62,T2:53)
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Unclear risk B - Unclear
Moon 1997 
 
 
Methods Multicenter (USA)
D: parallel
AC: Central data coordination center 
RC: telephone randomisation
B: physician and patient
ITT
Participants 981 participants with 2 or more biopsy proven BCC within the last 5 years (T1:490,T2:491). Two prior
BCCs T1:183,T2:193. Three to four prior BCCs T1:167, T2:166. >4 BCCs T1:140, T2: 132.
Excl: basal cell naevus syndrome, xeroderma pigmentosum, active malignancy, current evidence of hy-
perlipidaemia
Mean age T1: 61, T2: 61 yrs
Randomised: 981d
Evaluable: 899
Interventions T1: 2x5 mg isotretinoin capsules daily, T2: placebo identical in appearance.
Outcomes FU: week two, months three, six and then every six months for three yrs whilst on treatment . After
treatment six monthly for years four and five. Outcomes: Number of new BCCs and time to first appear-
ance of new BCC.
Tangrea 1992 
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Notes 82 participants lost to FU (T1:43, T2:39). Less than 20% of participants treatment regimen altered due
to adverse reactions.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Tangrea 1992  (Continued)
 
 
Methods D: parallel, multicentre, USA, Europe.
AC: clear
RS: generated by quality assurance department
B: participants, clinician, outcome assessor
PP
Participants Incl: Xeroderma pigmentosum participants with a history of AK or other skin cancer.
Excl: treatment within previous 30 days with drugs that would interfere with examination of skin le-
sions; pregnancy; breast feeding; inadequate contraception methods in women of childbearing age.
Set:
Median age: T1: 19.5, T2: 16
Duration: one yr
Randomised: 30 (T1:20, T2:10)
m/f: T1: 14/16, T2: 4/5
Evaluable: 29
Interventions T1: 1 mg/L T4 endonuclease V encapsulated in liposomes in a 1% hydrogel lotion
T2: placebo lotion consisted of equivalent empty liposomes, without enzyme, formulated in same lo-
tion.
liposome lotion
applied daily for one yr.
Outcomes FU: 3 monthly visits for 1 year, then 13 and 18 months. New AKs, BCC
Notes withdrawn: one placebo participants before treatment and one at nine months with progressive dis-
ease.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment
(selection bias)
Low risk A - Adequate
Yarosh 2001 
D: design
AC: method of allocation concealment
RS: method of generating randomisation sequence
B: blinding (participant, clinician, outcome assessment)
tx: treatment
CVA cerebrovascular accident
RTR: renal transplant recipients
T1: treatment one
T2: treatment two or placebo or control
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AK: actinic keratosis
BCCs: basal cell carcinomas
SCC: squamous cell carcinoma
IU: international units
M/f: males/females
ITT: intention to treat
PP: per protocol
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Dantal 1998 Looking at optimum doses of cyclosporin as used in maintenance therapy for kidney-transplant re-
cipients.
de Graaf 2006 PDT is not an intervention that this review is considering
Einspahr 2002 This study looked at reductions of AK and not numbers of BCC or SCC
Frieling 2001 Study was to test whether supplementation with beta carotene reduces risk for development of a
first NMSC in healthy males
Green 1994 Use of unselected adult population in Australia
Neale 2002 Sun protective products including sunscreens and sun blocks have been covered in another review
and therefore not included here.
Shigaki 2002 Looking at sun protection habits
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Randomised study of acitretin in patients with multiple prior skin cancers who received solid or-
gan transplantation.
Methods  
Participants Solid organ recipient receiving immunosuppressive agents, with two prior BCC or SCC respected
Interventions Oral acitretin or placebo daily for two years.
Outcomes  
Starting date  
Contact information  
Notes  
Pittelkow 
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Comparison 1.   Topical therapy vs placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Number of people with new
NMSC within the first year from
start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 T4N5 liposome lotion 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Number of people with new
BCC within the first year from
start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 T4N5 liposome lotion 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Number of people with new
SCC within the first year from
start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 T4N5 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Average number of new BCCs /
year
1   Difference lesion/yr (Random, 95% CI) Totals not selected
4.1 T4N5 liposome lotion 1   Difference lesion/yr (Random, 95% CI) 0.0 [0.0, 0.0]
5 Number of people with other
cancers
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 T4N5 liposome lotion 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Topical therapy vs placebo, Outcome 1 Number
of people with new NMSC within the first year from start of prevention.
Study or subgroup T4N5 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.1.1 T4N5 liposome lotion  
Yarosh 2001 10/20 6/9 0.75[0.4,1.42]
Favours T4N5 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Topical therapy vs placebo, Outcome 2 Number
of people with new BCC within the first year from start of prevention.
Study or subgroup T4N5 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.2.1 T4N5 liposome lotion  
Yarosh 2001 7/20 6/9 0.53[0.25,1.12]
Favours T4N5 100.1 50.2 20.5 1 Favours placebo
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Analysis 1.3.   Comparison 1 Topical therapy vs placebo, Outcome 3 Number
of people with new SCC within the first year from start of prevention.
Study or subgroup T4N5 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.3.1 T4N5  
Yarosh 2001 6/20 2/9 1.35[0.34,5.44]
Favours T4N5 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Topical therapy vs placebo, Outcome 4 Average number of new BCCs /year.
Study or subgroup Treatment Control Difference
lesion/yr
Difference lesion/yr Difference lesion/yr
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
1.4.1 T4N5 liposome lotion  
Yarosh 2001 1 1 -1.6 (0.612) -1.6[-2.8,-0.4]
Favours T4N5 42-4 -2 0 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Topical therapy vs placebo, Outcome 5 Number of people with other cancers.
Study or subgroup T4N5 Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.5.1 T4N5 liposome lotion  
Yarosh 2001 5/20 2/9 1.13[0.27,4.74]
Favours T4N5 100.1 50.2 20.5 1 Favours placebo
 
 
Comparison 2.   Retinoids vs placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Time to new NMSC 1   Hazard Ratio (Random, 95% CI) Totals not selected
1.1 Acetretin (OTR) 1   Hazard Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2 Time to new BCC 3   Hazard Ratio (Random, 95% CI) Subtotals only
2.1 Retinol (Previous NMSC) 2   Hazard Ratio (Random, 95% CI) 1.07 [0.91, 1.25]
2.2 Isotretinoin (previous
NMSC)
2   Hazard Ratio (Random, 95% CI) 1.01 [0.90, 1.14]
3 Time to new SCC 2   Hazard Ratio (Random, 95% CI) Subtotals only
3.1 Retinol (Previous NMSC) 2   Hazard Ratio (Random, 95% CI) 0.92 [0.57, 1.49]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.2 Isotretinoin vs placebo
(previous NMSC)
1   Hazard Ratio (Random, 95% CI) 1.79 [1.16, 2.76]
4 Number of people with new
NMSC within the first year from
start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Acetretin (OTR) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Number of people with a
new BCC within the first year
from start of prevention
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Retinol (previous NMSC) 1 347 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.88, 1.43]
5.2 Isotretinoin (previous
NMSC)
2 1333 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.83, 1.05]
6 Number of people with a
new SCC within the first year
from start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Retinol (previous NMSC) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Isotretinoin (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Number of people with a
new BCC at 2-5 yrs from start
of prevention
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Retinol (previous NMSC) 1 347 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.91, 1.22]
7.2 Isotretinoin (previous
NMSC)
2 1333 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.08]
8 Number of people with new
SCC at 2-5 yrs from start of pre-
vention
2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Retinol (previous NMSC) 2 2644 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.65, 1.53]
8.2 Isotretinoin (previous
NMSC)
1 352 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.79, 1.69]
9 Number of adverse events 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Acetretin (OTR) 2 67 Risk Ratio (M-H, Random, 95% CI) 1.80 [0.70, 4.61]
9.2 Retinol (previous NMSC) 1 2297 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.88, 1.42]
9.3 Isotretinoin (previous
NMSC)
1 981 Risk Ratio (M-H, Random, 95% CI) 1.76 [1.57, 1.97]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
10 Mortality end of study 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Retinol (previous NMSC) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Retinoids vs placebo, Outcome 1 Time to new NMSC.
Study or subgroup Retinoid Placebo log[Haz-
ard Ratio]
Hazard Ratio Hazard Ratio
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
2.1.1 Acetretin (OTR)  
Bouwes Bavinck 1995 1 1 -0.7 (0.995) 0.51[0.07,3.55]
Favours retinoids 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 2.2.   Comparison 2 Retinoids vs placebo, Outcome 2 Time to new BCC.
Study or subgroup Retinoids Placebo log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.2.1 Retinol (Previous NMSC)  
Levine 1997 1 1 0.1 (0.117) 47.65% 1.08[0.86,1.36]
Moon 1997 1 1 0.1 (0.112) 52.35% 1.06[0.85,1.32]
Subtotal (95% CI)       100% 1.07[0.91,1.25]
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.91); I2=0%  
Test for overall effect: Z=0.83(P=0.41)  
   
2.2.2 Isotretinoin (previous NMSC)  
Levine 1997 1 1 0 (0.119) 26.38% 1[0.79,1.26]
Tangrea 1992 1 1 0 (0.071) 73.62% 1.02[0.89,1.17]
Subtotal (95% CI)       100% 1.01[0.9,1.14]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
Favours retinoids 20.5 1.50.7 1 Favours placebo
 
 
Analysis 2.3.   Comparison 2 Retinoids vs placebo, Outcome 3 Time to new SCC.
Study or subgroup Retinoids Control log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.3.1 Retinol (Previous NMSC)  
Levine 1997 1 1 0.2 (0.221) 44.44% 1.21[0.78,1.87]
Moon 1997 1 1 -0.3 (0.149) 55.56% 0.74[0.55,0.99]
Subtotal (95% CI)       100% 0.92[0.57,1.49]
Heterogeneity: Tau2=0.09; Chi2=3.41, df=1(P=0.06); I2=70.64%  
Favours Retinoids 100.1 50.2 20.5 1 Favours placebo
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Study or subgroup Retinoids Control log[Hazard
Ratio]
Hazard Ratio Weight Hazard Ratio
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=0.34(P=0.74)  
   
2.3.2 Isotretinoin vs placebo (previous NMSC)  
Levine 1997 1 1 0.6 (0.221) 100% 1.79[1.16,2.76]
Subtotal (95% CI)       100% 1.79[1.16,2.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.64(P=0.01)  
Favours Retinoids 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 2.4.   Comparison 2 Retinoids vs placebo, Outcome 4 Number
of people with new NMSC within the first year from start of prevention.
Study or subgroup Retinoid Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.4.1 Acetretin (OTR)  
Bouwes Bavinck 1995 2/19 9/19 0.22[0.06,0.9]
Favours retinoid 1000.01 100.1 1 Favours placebo
 
 
Analysis 2.5.   Comparison 2 Retinoids vs placebo, Outcome 5 Number
of people with a new BCC within the first year from start of prevention.
Study or subgroup Retinoid Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 Retinol (previous NMSC)  
Levine 1997 78/173 70/174 100% 1.12[0.88,1.43]
Subtotal (95% CI) 173 174 100% 1.12[0.88,1.43]
Total events: 78 (Retinoid), 70 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.91(P=0.36)  
   
2.5.2 Isotretinoin (previous NMSC)  
Levine 1997 67/178 70/174 20.86% 0.94[0.72,1.22]
Tangrea 1992 220/490 236/491 79.14% 0.93[0.82,1.07]
Subtotal (95% CI) 668 665 100% 0.93[0.83,1.05]
Total events: 287 (Retinoid), 306 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=1.11(P=0.27)  
Favours retinoid 100.1 50.2 20.5 1 Favours placebo
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Analysis 2.6.   Comparison 2 Retinoids vs placebo, Outcome 6 Number
of people with a new SCC within the first year from start of prevention.
Study or subgroup Retinoid Placbeo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.6.1 Retinol (previous NMSC)  
Levine 1997 32/173 21/174 1.53[0.92,2.55]
   
2.6.2 Isotretinoin (previous NMSC)  
Levine 1997 19/178 21/174 0.88[0.49,1.59]
Favours retinoid 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 2.7.   Comparison 2 Retinoids vs placebo, Outcome 7
Number of people with a new BCC at 2-5 yrs from start of prevention.
Study or subgroup Retinoid Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.7.1 Retinol (previous NMSC)  
Levine 1997 119/173 114/174 100% 1.05[0.91,1.22]
Subtotal (95% CI) 173 174 100% 1.05[0.91,1.22]
Total events: 119 (Retinoid), 114 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
   
2.7.2 Isotretinoin (previous NMSC)  
Levine 1997 117/178 114/174 25.51% 1[0.86,1.17]
Tangrea 1992 327/490 327/491 74.49% 1[0.92,1.09]
Subtotal (95% CI) 668 665 100% 1[0.93,1.08]
Total events: 444 (Retinoid), 441 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=0.06(P=0.95)  
Favours retinoid 20.5 1.50.7 1 Favours placebo
 
 
Analysis 2.8.   Comparison 2 Retinoids vs placebo, Outcome 8
Number of people with new SCC at 2-5 yrs from start of prevention.
Study or subgroup Retinoid Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.8.1 Retinol (previous NMSC)  
Levine 1997 48/173 38/174 44.55% 1.27[0.88,1.84]
Moon 1997 113/1157 136/1140 55.45% 0.82[0.65,1.04]
Subtotal (95% CI) 1330 1314 100% 1[0.65,1.53]
Total events: 161 (Retinoid), 174 (Placebo)  
Heterogeneity: Tau2=0.07; Chi2=3.87, df=1(P=0.05); I2=74.19%  
Test for overall effect: Z=0.02(P=0.98)  
   
2.8.2 Isotretinoin (previous NMSC)  
Levine 1997 45/178 38/174 100% 1.16[0.79,1.69]
Subtotal (95% CI) 178 174 100% 1.16[0.79,1.69]
Favours retinoid 100.1 50.2 20.5 1 Favours placebo
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Study or subgroup Retinoid Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 45 (Retinoid), 38 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
Favours retinoid 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 2.9.   Comparison 2 Retinoids vs placebo, Outcome 9 Number of adverse events.
Study or subgroup Retinoid Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.9.1 Acetretin (OTR)  
Bouwes Bavinck 1995 1/21 1/23 12.06% 1.1[0.07,16.43]
George 2002 9/14 3/9 87.94% 1.93[0.71,5.26]
Subtotal (95% CI) 35 32 100% 1.8[0.7,4.61]
Total events: 10 (Retinoid), 4 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=1.23(P=0.22)  
   
2.9.2 Retinol (previous NMSC)  
Moon 1997 127/1157 112/1140 100% 1.12[0.88,1.42]
Subtotal (95% CI) 1157 1140 100% 1.12[0.88,1.42]
Total events: 127 (Retinoid), 112 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
   
2.9.3 Isotretinoin (previous NMSC)  
Tangrea 1992 373/490 212/491 100% 1.76[1.57,1.97]
Subtotal (95% CI) 490 491 100% 1.76[1.57,1.97]
Total events: 373 (Retinoid), 212 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=9.84(P<0.0001)  
Favours retinoid 200.05 50.2 1 Favours placebo
 
 
Analysis 2.10.   Comparison 2 Retinoids vs placebo, Outcome 10 Mortality end of study.
Study or subgroup Retinoid Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.10.1 Retinol (previous NMSC)  
Moon 1997 62/1157 53/1140 1.15[0.81,1.65]
Favours retinoid 100.1 50.2 20.5 1 Favours placebo
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Comparison 3.   Antioxidant vs placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Time to new NMSC 2   Hazard Ratio (Random, 95% CI) Totals not selected
1.1 Selenium (Previous
NMSC)
1   Hazard Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Beta carotene (Previous
NMSC)
1   Hazard Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
2 Time to new BCC 1   Hazard Ratio (Random, 95% CI) Totals not selected
2.1 Selenium (Previous
NMSC)
1   Hazard Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
3 Time to new SCC 1   Hazard Ratio (Random, 95% CI) Totals not selected
3.1 Selenium (previous
NMSC)
1   Hazard Ratio (Random, 95% CI) 0.0 [0.0, 0.0]
4 Number of people with new
NMSC within the first year
from start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4.1 Beta carotene (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Number of people with a
NMSC at 2-5 years from start
of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5.1 Beta carotene (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 Number of people with a
new BCC at 2-5 yrs from start
of prevention
2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
6.1 Selenium (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Beta carotene (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Number of people with new
SCC at 2-5 yrs from start of
prevention
2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Selenium (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Beta carotene (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
8 Number of people with oth-
er cancers
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Selenium (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Number of adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
9.1 Selenium (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Mortality end of study 2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
10.1 Selinium (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Beta carotene (previous
NMSC)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 3.1.   Comparison 3 Antioxidant vs placebo, Outcome 1 Time to new NMSC.
Study or subgroup Antioxidant Placebo log[Haz-
ard Ratio]
Hazard Ratio Hazard Ratio
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
3.1.1 Selenium (Previous NMSC)  
Clark 1996 1 1 0.2 (0.069) 1.17[1.02,1.34]
   
3.1.2 Beta carotene (Previous NMSC)  
Greenberg 1990 1 1 0 (0.07) 1.03[0.9,1.18]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.2.   Comparison 3 Antioxidant vs placebo, Outcome 2 Time to new BCC.
Study or subgroup Antioxidant Placebo log[Haz-
ard Ratio]
Hazard Ratio Hazard Ratio
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
3.2.1 Selenium (Previous NMSC)  
Clark 1996 1 1 0.1 (0.074) 1.09[0.94,1.26]
Favours antioxidant 20.5 1.50.7 1 Favours placebo
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Analysis 3.3.   Comparison 3 Antioxidant vs placebo, Outcome 3 Time to new SCC.
Study or subgroup Antioxidant Control log[Haz-
ard Ratio]
Hazard Ratio Hazard Ratio
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
3.3.1 Selenium (previous NMSC)  
Clark 1996 1 1 0.2 (0.096) 1.25[1.03,1.51]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.4.   Comparison 3 Antioxidant vs placebo, Outcome 4 Number
of people with new NMSC within the first year from start of prevention.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.4.1 Beta carotene (previous NMSC)  
Greenberg 1990 153/913 145/892 1.03[0.84,1.27]
Favours antioxidant 1000.01 100.1 1 Favours placebo
 
 
Analysis 3.5.   Comparison 3 Antioxidant vs placebo, Outcome 5
Number of people with a NMSC at 2-5 years from start of prevention.
Study or subgroup Antioxidant Placbeo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.5.1 Beta carotene (previous NMSC)  
Greenberg 1990 362/913 340/892 1.04[0.93,1.17]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.6.   Comparison 3 Antioxidant vs placebo, Outcome 6
Number of people with a new BCC at 2-5 yrs from start of prevention.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.6.1 Selenium (previous NMSC)  
Clark 1996 377/653 350/659 1.09[0.99,1.2]
   
3.6.2 Beta carotene (previous NMSC)  
Greenberg 1990 334/913 317/892 1.03[0.91,1.16]
Favours antioxidant 20.5 1.50.7 1 Favours placebo
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Analysis 3.7.   Comparison 3 Antioxidant vs placebo, Outcome 7
Number of people with new SCC at 2-5 yrs from start of prevention.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.7.1 Selenium (previous NMSC)  
Clark 1996 218/653 190/659 1.16[0.99,1.36]
   
3.7.2 Beta carotene (previous NMSC)  
Greenberg 1990 73/913 59/892 1.21[0.87,1.68]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.8.   Comparison 3 Antioxidant vs placebo, Outcome 8 Number of people with other cancers.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.8.1 Selenium (previous NMSC)  
Clark 1996 77/653 119/659 0.65[0.5,0.85]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.9.   Comparison 3 Antioxidant vs placebo, Outcome 9 Number of adverse events.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.9.1 Selenium (previous NMSC)  
Clark 1996 21/653 14/659 1.51[0.78,2.95]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 3.10.   Comparison 3 Antioxidant vs placebo, Outcome 10 Mortality end of study.
Study or subgroup Antioxidant Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
3.10.1 Selinium (previous NMSC)  
Clark 1996 108/653 129/659 0.84[0.67,1.07]
   
3.10.2 Beta carotene (previous NMSC)  
Greenberg 1990 79/913 72/892 1.07[0.79,1.46]
Favours antioxidant 100.1 50.2 20.5 1 Favours placebo
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Comparison 4.   Di<erent doses of acitretin
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 adverse events 1   Risk Ratio (M-H, Random, 95% CI) Totals not select-
ed
1.1 Acetretin 0.4mg/Kg/d over 1 yr vs 0.4mg/
Kg/d for 3 months then 0.2mg/Kg/d for 9
months (OTR)
1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 Di<erent doses of acitretin, Outcome 1 adverse events.
Study or subgroup High dose Low dose Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
4.1.1 Acetretin 0.4mg/Kg/d over 1 yr vs 0.4mg/Kg/d for 3 months then 0.2mg/Kg/d for 9
months (OTR)
 
de Sevaux 2003 2/14 5/12 0.34[0.08,1.46]
Favours high dose 100.1 50.2 20.5 1 Favours low dose
 
 
Comparison 5.   Reduced fat diet vs normal diet
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Number of people with new NMSC
within first year from start of preven-
tion
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Reduced fat diet (previous NMSC) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Number of people with a NMSC at 2-5
years from start of prevention
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Reduced fat diet (previous NMSC) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Mortality end of study 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 Reduced fat diet (previous NMSC) 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 5.1.   Comparison 5 Reduced fat diet vs normal diet, Outcome 1
Number of people with new NMSC within first year from start of prevention.
Study or subgroup Reduced fat diet Normal diet Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
5.1.1 Reduced fat diet (previous NMSC)  
Favours reduced fat 100.1 50.2 20.5 1 Favours normal diet
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Study or subgroup Reduced fat diet Normal diet Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Black 1995 8/51 6/50 1.31[0.49,3.5]
Favours reduced fat 100.1 50.2 20.5 1 Favours normal diet
 
 
Analysis 5.2.   Comparison 5 Reduced fat diet vs normal diet, Outcome
2 Number of people with a NMSC at 2-5 years from start of prevention.
Study or subgroup Reduced fat diet Normal diet Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
5.2.1 Reduced fat diet (previous NMSC)  
Black 1995 1/51 6/50 0.16[0.02,1.31]
Favours reduced fat 1000.01 100.1 1 Favours normal diet
 
 
Analysis 5.3.   Comparison 5 Reduced fat diet vs normal diet, Outcome 3 Mortality end of study.
Study or subgroup Reduced fat diet Normal diet Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
5.3.1 Reduced fat diet (previous NMSC)  
Black 1995 1/58 2/57 0.49[0.05,5.27]
Favours reduced fat 200.05 50.2 1 Favours normal diet
 
 
A D D I T I O N A L   T A B L E S
 
Study Alloca-
tion gen
Alloca-
tion con-
ceal
Blinding Loss to
FU
Analysis
method
Type of participant
Clark 1996 yes yes Participant, physi-
cian
nine PP Previous BCC or SCC
Black 1995 Yes No outcome assessor 14 PP Previous NMSC
Bouwes Bavinck
1995
Yes Yes Physician, partici-
pant
six PP RTR
de Sevaux 2003 Yes No Outcome assessor:
unclear
two with-
drew
ITT RTR
George 2002 No No None 12 with-
drew
ITT RTR
Greenberg 1990 Yes Yes Physician, partici-
pant, outcome asses-
sor
93 + 178 ITT Previous NMSC
Table 1.   Quality components 
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Levine 1997 No No Physician, partici-
pant
0 ITT Previous NMSC
Moon 1997 Yes No Participant, outcome
assessor
334 ITT History of AKs, SCC or BCC
Tangrea 1992 Yes Yes Physician, partici-
pants
82 ITT Previous NMSC
Yarosh 2001 Yes Yes Participant, physi-
cian, outcome asses-
sor
two par-
ticipants
with-
drawn
PP Participants with Xeroderma
pigmentosum and a history of
AKs or other skin cancer
Table 1.   Quality components  (Continued)
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Appendix 1. Cochrane Library (CLIB) search strategy
 
#1 non-melanoma skin cancer in Abstract or NMSC in Abstract or basal cell carcinoma in Abstract or BCC in Abstract or squamous
cell carcinoma in Abstract in all products #2 SCC in Abstract or organ transplant recipient in Abstract or xeroderma pigmentosum in
Abstract or gorlin* syndrome in Abstract or arsenic in Abstract in all products #3 AIDS or (acquired immunodeficiency syndrome) in
Abstract or immunocompromis* in Abstract or albinism in Abstract or bowen* disease in Abstract or solar keratos* in Abstract in all
products #4 burn* or scar* in Abstract or recessive dystrophic epidermolysis bullosa in Abstract or PUVA in Abstract or psoralen ultra
violet in Abstract in all products #5 sunscreen* in Abstract or antioxidant* in Abstract or retinoid* in Abstract or selenium in Abstract
or beta carotene in Abstract in all products #6 vitamin A in All Fields or vitamin E in All Fields or diet* NEAR/2 modification* in Abstract
or diet* NEAR/2 fat* in Abstract or complementary NEAR/2 therap* in Abstract in all products #7 complementary NEAR/2 medicine* in
Abstract or phytochemical* in All Fields or green tea* in All Fields in all products #8 (#1 OR #2 OR #3 OR #4) #9 (#5 OR #6 OR #7) #10 (#8
AND #9) #11 SR-SKIN in All Fields in all products #12 (#10 AND NOT #11)
 
 
Appendix 2. MEDLINE (OVID) search strategy
 
1. RANDOMIZED CONTROLLED TRIAL.pt.
2. CONTROLLED CLINICAL TRIAL.pt.
3. RANDOMIZED CONTROLLED TRIALS.sh.
4. RANDOM ALLOCATION.sh.
5. DOUBLE BLIND METHOD.sh.
6. SINGLE-BLIND METHOD.sh.
7. or/1-6
8. animal/ not human/
9. 7 not 8
10. CLINICAL TRIAL.pt.
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
14. PLACEBOS.sh.
15. placebo$.ti,ab.
16. random$.ti,ab.
17. RESEARCH DESIGN.sh.
18. or/10-17
19. 18 not 8
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20. 19 not 9
21. COMPARATIVE STUDY.pt.
22. exp EVALUATION STUDIES/
23. FOLLOW UP STUDIES.sh.
24. PROSPECTIVE STUDIES.sh.
25. (control$ or prospectiv$ or volunteer$).ti,ab.
26. or/21-25
27. 26 not 8
28. 27 not (9 or 20)
29. 9 or 20 or 28
30. *Carcinoma, Squamous Cell/ or *Skin Neoplasms/ or non-melanoma skin cancer.mp. or *Carcinoma, Basal Cell/
31. *Xeroderma pigmentosum/
32. *Precancerous Conditions/
33. *Neoplasms, Radiation-Induced/
34. *Organ Transplantation/ or organ transplant recipients.mp.
35. *Immunosuppression/
36. *Immunocompromised Host/
37. *Acquired Immunodeficiency Syndrome/
38. *Arsenic Poisoning/ or *Arsenic/
39. *Albinism, Ocular/ or albinism.mp. or *Albinism/ or *Albinism, Oculocutaneous/
40. gorlin$ syndrome.mp. or *Basal Cell Nevus Syndrome/
41. *epidermolysis bullosa/ or *epidermolysis bullosa dystrophica/ or skin diseases, genetic/
42. recessive dystrophic epidermolysis bullosa.mp.
43. RDEB-HS.mp.
44. *PUVA Therapy/
45. *burns/ or *sunburn/
46. previous nmsc.mp.
47. *retinoids/ or *vitamin a/
48. *Selenium/
49. *beta Carotene/
50. vitamin C.mp. or *Ascorbic Acid/
51. *Vitamin E/
52. exp Antioxidants/
53. *Isoniazid/
54. *Food Habits/
55. *obesity/ or *dietary fats/
56. exp Complementary Therapies/
57. *flavonoids/ or *catechin/ or *phenols/
58. *phytochemicals/ or *tea/ or *plant extracts/
59. *Drugs, Chinese Herbal/
60. *Medicine, Herbal/
61. *Medicine, Traditional/
62. green tea.mp.
63. *acupuncture therapy/ or *homeopathy/ or *holistic health/
64. *musculoskeletal manipulations/ or *natural childbirth/
65. *Relaxation Techniques/ or mind-body relaxation techniques.mp.
66. *reflexology/ or *rejuvenation/ or *sensory art therapies/ or exp spiritual therapies/
67. exp Primary Prevention/
68. exp Chemoprevention/
69. 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46
70. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68
71. 29 and 69 and 70
72. limit 71 to yr="2003 - 2007"
 
 
Appendix 3. EMBASE (OVID) search strategy
 
1. random$.mp.
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2. factorial$.mp.
3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. *Carcinoma, Squamous Cell/ or *Skin Neoplasms/ or non-melanoma skin cancer.mp. or *Carcinoma, Basal Cell/
15. *Xeroderma pigmentosum/
16. *Precancerous Conditions/
17. *Neoplasms, Radiation-Induced/
18. *Organ Transplantation/ or organ transplant recipients.mp.
19. *Immunosuppression/
20. *Immunocompromised Host/
21. *Acquired Immunodeficiency Syndrome/
22. *Arsenic Poisoning/ or *Arsenic/
23. *Albinism, Ocular/ or albinism.mp. or *Albinism/ or *Albinism, Oculocutaneous/
24. gorlin$ syndrome.mp. or *Basal Cell Nevus Syndrome/
25. *epidermolysis bullosa/ or *epidermolysis bullosa dystrophica/ or skin diseases, genetic/
26. recessive dystrophic epidermolysis bullosa.mp.
27. RDEB-HS.mp.
28. *PUVA Therapy/
29. *burns/ or *sunburn/
30. previous nmsc.mp.
31. *retinoids/ or *vitamin a/
32. *Selenium/
33. *beta Carotene/
34. vitamin C.mp. or *Ascorbic Acid/
35. *Vitamin E/
36. exp Antioxidants/
37. *Isoniazid/
38. *Food Habits/
39. *obesity/ or *dietary fats/
40. exp Complementary Therapies/
41. *flavonoids/ or *catechin/ or *phenols/
42. *phytochemicals/ or *tea/ or *plant extracts/
43. *Drugs, Chinese Herbal/
44. *Medicine, Herbal/
45. *Medicine, Traditional/
46. green tea.mp.
47. *acupuncture therapy/ or *homeopathy/ or *holistic health/
48. *musculoskeletal manipulations/ or *natural childbirth/
49. *Relaxation Techniques/ or mind-body relaxation techniques.mp.
50. *reflexology/ or *rejuvenation/ or *sensory art therapies/ or exp spiritual therapies/
51. exp Primary Prevention/
52. exp Chemoprevention/
53. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
54. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52
55. 13 and 53 and 54
56. limit 55 to yr="2005 - 2007"
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W H A T ' S   N E W
 
Date Event Description
18 February 2015 Amended This review is going to be updated. We have written a published
note to say that the original review is being updated by way of 2
new titles.
 
H I S T O R Y
Protocol first published: Issue 3, 2005
Review first published: Issue 4, 2007
 
Date Event Description
23 May 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
Link with editorial base and co-ordinate contributions from co-authors (FB-H)
DraM Protocol (FB-H, NS)
Consumer input to protocol (JD)
Advice on transplant patients (AW)
Run search (FB-H, NS)
Identify relevant titles and abstracts from searches (FB-H, J L-B, NS)
Obtain copies of trials ( FB-H, NS, J L-B)
Selection of trials (FB-H, NS)
Extract data from trials (FB-H, J L-B, NS)
Enter data into RevMan (FB-H, J L-B)
Carry out analysis (FB-H, J L-B)
Interpret data (FB-H, J L-B, WP)
D E C L A R A T I O N S   O F   I N T E R E S T
None known.
S O U R C E S   O F   S U P P O R T
Internal sources• University Nottingham, UK.
External sources• No sources of support supplied
N O T E S
This review is being updated by way of 2 new titles (Interventions for preventing keratinocyte carcinoma (non-melanoma skin
cancer) in solid organ transplant recipients and Interventions for preventing keratinocyte cancer in high-risk groups not receiving
immunosuppressive therapy), because transplant patients are a distinct group.
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
Carcinoma, Basal Cell  [etiology]  [*prevention & control];  Carcinoma, Squamous Cell  [etiology]  [*prevention & control];  Neoplasms,
Radiation-Induced  [prevention & control];  Randomized Controlled Trials as Topic;  Risk Factors;  Skin Neoplasms  [etiology]
 [*prevention & control];  Sunlight  [adverse eCects]
MeSH check words
Humans
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